Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Head and Neck Neoplasms*/therapy ; Rhabdomyosarcoma*/pathology; Adult ; Humans ; Middle Aged ; Japan ; Neoplasm Recurrence, Local/therapy ; Retrospective Studies ; Salvage Therapy
    • Abstract:
      Background: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy.
      Methods: We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy.
      Results: Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 - 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 - 25.8 months): 17.1 months (95%CI: 6.0 - not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 - 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months-NR): 40.8 months (95%CI: 12.1 - NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions.
      Conclusion: The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.
      (© 2023. The Author(s).)
    • References:
      Ann Oncol. 2014 Jan;25(1):231-6. (PMID: 24356633)
      Nat Genet. 2019 Dec;51(12):1714-1722. (PMID: 31784732)
      Pediatr Blood Cancer. 2013 Aug;60(8):1267-73. (PMID: 23418028)
      Mod Pathol. 2016 Dec;29(12):1532-1540. (PMID: 27562493)
      Pediatr Blood Cancer. 2005 Apr;44(4):338-47. (PMID: 15503297)
      JCI Insight. 2022 Dec 8;7(23):. (PMID: 36282590)
      J Clin Oncol. 2012 Jul 10;30(20):2457-65. (PMID: 22665534)
      J Clin Med. 2021 Feb 17;10(4):. (PMID: 33671214)
      Med Oncol. 2019 May 18;36(7):59. (PMID: 31104202)
      J Clin Oncol. 2010 Oct 20;28(30):4658-63. (PMID: 20837952)
      J Clin Oncol. 2008 May 10;26(14):2384-9. (PMID: 18467730)
      Otolaryngol Head Neck Surg. 2011 Dec;145(6):967-73. (PMID: 21873599)
      Int J Mol Sci. 2022 Mar 25;23(7):. (PMID: 35408939)
      Eur J Cancer. 2022 Sep;172:367-386. (PMID: 35839732)
      J Clin Oncol. 2021 Sep 10;39(26):2859-2871. (PMID: 34166060)
      J Clin Oncol. 2009 Nov 1;27(31):5182-8. (PMID: 19770373)
      J Clin Oncol. 2012 May 10;30(14):1670-7. (PMID: 22454413)
      J Clin Oncol. 2016 Jan 10;34(2):117-22. (PMID: 26503200)
      Pediatr Blood Cancer. 2023 May 26;:e30436. (PMID: 37243336)
      J Clin Oncol. 2009 Jul 10;27(20):3391-7. (PMID: 19398574)
      J Clin Oncol. 1999 Nov;17(11):3487-93. (PMID: 10550146)
      PLoS One. 2011 Feb 23;6(2):e17127. (PMID: 21373200)
      Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006669. (PMID: 21154373)
      J Clin Oncol. 2019 Nov 1;37(31):2866-2874. (PMID: 31513481)
      Front Oncol. 2023 Aug 18;13:1244035. (PMID: 37664028)
      Pediatr Blood Cancer. 2011 Dec 15;57(7):1261-5. (PMID: 21826783)
      Cancer Med. 2013 Aug;2(4):553-63. (PMID: 24156028)
      J Clin Oncol. 2002 Jun 1;20(11):2672-9. (PMID: 12039929)
      Cancer Discov. 2014 Feb;4(2):216-31. (PMID: 24436047)
      Otolaryngol Head Neck Surg. 2017 Jul;157(1):135-141. (PMID: 28669309)
      Eur J Cancer. 2021 Jul;151:84-93. (PMID: 33971448)
      Cancer Chemother Pharmacol. 2012 Sep;70(3):391-7. (PMID: 22806306)
      Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e27-e35. (PMID: 31350181)
      Histopathology. 2022 Jan;80(1):98-108. (PMID: 34958505)
      Asia Pac J Clin Oncol. 2020 Apr;16(2):e47-e52. (PMID: 31657883)
      Cancer. 2003 Aug 1;98(3):571-80. (PMID: 12879475)
      J Pathol. 2014 Feb;232(3):300-7. (PMID: 24272621)
      Cancer Med. 2018 Aug;7(8):4023-4035. (PMID: 29956493)
    • Contributed Indexing:
      Keywords: Adult; Head and neck; Para-meningeal; Rhabdomyosarcoma; Salvage
    • Publication Date:
      Date Created: 20231031 Date Completed: 20240122 Latest Revision: 20240122
    • Publication Date:
      20240123
    • Accession Number:
      PMC10617040
    • Accession Number:
      10.1186/s12885-023-11528-4
    • Accession Number:
      37904096